No profile data available.
Ocular Therapeutix, Inc. (OCUL) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Bedford, United States, with about 325 full-time employees.
It reported revenue of $51.95 million for fiscal year 2025, down 18.5% from fiscal year 2024, and net income of -$265.94 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $13.48 million, up 0.1% from a year before. Its market capitalization was $1.66 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
Ocular Therapeutix reported $51.95 million in revenue for fiscal year 2025, down 18.5% from $63.72 million in fiscal year 2024. In Q2 2026 revenue was $13.48 million.
$1.66 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Intellia Therapeutics, Inc. (NTLA), Xencor, Inc. (XNCR), ANI Pharmaceuticals, Inc. (ANIP), Immunocore Holdings plc (IMCR).